USPTO Examiner CHEN CATHERYNE - Art Unit 1655

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19242278CLINICAL DRESSING LOADED WITH COFFEE EXTRACTJune 2025January 2026Allow710NoNo
19241614CLINICAL DRESSING LOADED WITH COFFEE EXTRACTJune 2025February 2026Allow810NoNo
18826102MODIFICATION OF NATURAL COMPOUNDS TO CREATE PRODUCTS WITH ENHANCED HEALTH BENEFITSSeptember 2024June 2025Allow911YesNo
18745674COMPOSITIONS AND METHOD FOR TREATING AND PREVENTING COMPLICATIONS OF OBESITYJune 2024April 2025Allow1011NoNo
18679420CLINICAL DRESSING LOADED WITH COFFEE EXTRACTMay 2024June 2025Allow1211NoNo
18234592STABLE VITAMIN C COMPOSITIONSAugust 2023January 2026Allow2911NoNo
18232767FORMULATIONS CONTAINING OMEGA-3 FATTY ACIDS OR ESTERS THEREOF AND MAQUI BERRY EXTRACT AND THERAPEUTIC USES THEREOFAugust 2023November 2025Abandon2710NoNo
18353570COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERSJuly 2023March 2025Allow2011NoNo
18345075METHODS AND COMPOSITIONS WITH PURIFIED BOMBYX MORI COCOON SILK PEPTIDE FIBER AND REFINED BUGLOSSOIDES ARVENSIS SEED OIL PROVIDING ANTI-INFLAMMATORY EFFECTS AND NEUROPROTECTION FOR DISEASE STATESJune 2023September 2024Allow1410NoNo
18259881METHODS FOR ENHANCING MUSCLE PERFORMANCE OR REDUCING CHRONIC FATIGUE BY ADMINISTERING BOVINE MILK-DERIVED EXOSOMESJune 2023March 2026Abandon3301NoNo
18205436COMPOSITION FOR PREVENTING OR TREATING SLEEP DISORDERS, CONTAINING ENZYME-TREATED ASHWAGANDHA EXTRACT AS ACTIVE INGREDIENTJune 2023October 2025Allow2820YesNo
18203772Method for Synthesizing a Silver Nanoparticle Composition from Rhynchophorus ferrugineus Larvae OlivierMay 2023September 2024Allow1620NoNo
18324829COMPOSITIONS AND METHODS FOR IMPROVING GUT HEALTHMay 2023December 2025Allow3110NoNo
18185991COMPOSITIONMarch 2023January 2026Abandon3411NoNo
18121471WATER-BASED INSECT REPELLENT COMPOSITIONMarch 2023January 2025Allow2220NoNo
18145278USE OF ADVANCED PLATELET-RICH FIBRIN IN PREPARING MEDICAMENT FOR TREATMENT OF DIABETIC FOOT ULCERDecember 2022March 2026Abandon3911NoNo
18080825COMPOSITION FOR ENHANCING COGNITIVE ABILITIES AND USE THEREOFDecember 2022December 2025Abandon3610NoNo
18070078COMPOSITION FOR PREVENTING OR TREATING SLEEP DISORDERS, CONTAINING ENZYME-TREATED ASHWAGANDHA EXTRACT AS ACTIVE INGREDIENTNovember 2022October 2023Abandon1010NoNo
17951917TERPENE-CONTAINING COMPOSITIONSSeptember 2022March 2024Abandon1701NoNo
17934408NOVEL COMPOSITIONSeptember 2022October 2025Abandon3721NoNo
17912592COMPOSITION FOR TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES COMPRISING COMPOSITE EXTRACT OF BEET, RED ONION AND PURPLE SWEET POTATO AS ACTIVE INGREDIENTSSeptember 2022August 2025Abandon3510NoNo
17880086METHOD FOR DEODORIZING KONJAC TUBER EXTRACT OR KONJAC TOBIKO CONTAINING GLUCOSYLCERAMIDEAugust 2022October 2024Allow2620YesNo
17865943COMPOSITIONS FOR CONTROLLING ARTHROPODSJuly 2022August 2025Abandon3721NoNo
17852803POMEGRANATE OIL FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASESJune 2022May 2025Allow3520NoNo
17841323METHANOL-BASED EXTRACTION OF PSYCHOACTIVE ALKALOIDS FROM FUNGUSJune 2022January 2025Allow3131NoYes
17836897WATER-BASED INSECT REPELLENT COMPOSITIONJune 2022January 2023Allow811YesNo
17663932NATURAL PEST REPELLANT FORMULATIONS AND METHODS OF USEMay 2022April 2024Abandon2301NoNo
17733623COMPOSITION FOR IMPROVED ENERGY, FOCUS AND CLARITYApril 2022August 2024Abandon2811NoNo
17721343METHODS AND COMPOSITIONS WITH PURIFIED BOMBYX MORI COCOON SILK PEPTIDE FIBER AND REFINED BUGLOSSOIDES ARVENSIS SEED OIL PROVIDING ANTI-INFLAMMATORY EFFECTS AND NEUROPROTECTION FOR DISEASE STATESApril 2022April 2023Allow1211YesNo
17716525ORAL SUPPLEMENTS CONTAINING ENRICHED PHENOLIC COMPOUND EXTRACTS COMBINED WITH ORGANIC ACID SODIUM SALTS, CREATINES AND/OR CREATINE SALTSApril 2022June 2025Allow3821YesNo
17699348COMPOSITION COMPRISING PRUNUS PERSICA EXTRACTMarch 2022April 2024Abandon2410NoNo
17642645COMPOSITIONS COMPRISING NATURAL EXTRACTS FOR STIMULATING THE IMMUNE RESPONSEMarch 2022April 2024Abandon2521NoNo
17690506METHODS, ANHYDROUS COMPOSITIONS AND APPLICATORS FOR DELIVERY OF NUTRITIONAL SUPPLEMENTS WHILE CONCURRENTLY/SIMULTANEOUSLY PROVIDING AROMATHERAPYMarch 2022May 2024Abandon2701NoNo
17690028Pharmaceutical Composition for Treating Oral Ulcer and Preparation Method and Application ThereofMarch 2022August 2023Allow1700NoNo
17652432PROMOTION OF LYMPHATIC FUNCTIONFebruary 2022January 2024Allow2301NoNo
17679355MATERIALS AND METHODS FOR BLOCKING MALARIA INFECTION AND TRANSMISSIONFebruary 2022May 2023Abandon1411NoNo
17669581NUTRITIONAL FORMULATION FOR CANCER PREVENTIONFebruary 2022March 2024Abandon2501NoNo
17634364SKIN-CARE COMPOSITIONS AND USES THEREOFFebruary 2022May 2025Abandon3901NoNo
17591838SPECIFIC NUTRITIONAL OR THERAPEUTIC AGENT INCLUDING A MIXTURE OF GRAPE AND BLUEBERRYFebruary 2022December 2024Allow3411NoNo
17589746COMPOSITIONS AND METHODS FOR TREATING TRAVELER'S DIARRHEAJanuary 2022September 2024Allow3211NoNo
17576922Compositions and Methods for Treating and Removing Seborrheic KeratosesJanuary 2022October 2023Allow2111NoNo
17576502COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERSJanuary 2022March 2024Allow2611NoNo
17573783COMPOSITION FOR STRENGTHENING SKIN BARRIER OR MOISTURIZING SKIN COMPRISING TILIANINJanuary 2022November 2024Abandon3421NoNo
17626707METHODS FOR ISOLATING ESSENTIAL OILS, PHYTOCHEMICALS AND PHARMACEUTICALLY ACTIVE COMPONENTS FROM BIOMASS AND RECONSTITUTING SYNTHETIC FORMULATIONS COMPRISING SAMEJanuary 2022May 2025Abandon4001NoNo
17573060NUTRACEUTICAL FORMULATION FOR UNBLOCKING RECEPTORSJanuary 2022March 2025Abandon3801NoNo
17565948DIAPER CREAMDecember 2021December 2025Allow4731YesNo
17537858METHOD FOR TREATING OR PREVENTING INFLAMMATIONNovember 2021June 2024Abandon3020NoNo
17613522MODIFIED BLACK SOLDIER FLY LARVAE OIL WITH MODIFIED LAURIC ACID FOR TREATMENT AGAINST BIOFILM FORMATION AND MICROORGANISM GROWTHNovember 2021March 2025Abandon4001NoNo
17533211METHOD OF PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS USING SOPHORA JAPONICA L. EXTRACT AS ACTIVE INGREDIENTNovember 2021August 2025Abandon4531NoNo
17610507COMPOSITIONS COMPRISING PLANT EXTRACTS AND OILS AND RELATED METHODS OF TREATMENT AND THEIR PREPARATIONNovember 2021March 2025Abandon4001NoNo
17521679METHODS FOR REDUCING NEGATIVE EFFECTS OF ALCOHOL CONSUMPTIONNovember 2021September 2025Abandon4731NoNo
17519859METHODS FOR OPTIMIZED CANNABINOID DOSAGE DETERMINATIONNovember 2021March 2025Abandon4001NoNo
17518799ANTIDIABETIC COMPOSITION COMPRISING GINGER EXTRACT OBTAINED FROM MICROWAVE-PROCESSED GINGER AND METHOD OF PREVENTING OR TREATING DIABETIS MELLITUSNovember 2021November 2024Abandon3621NoNo
17608490MAQUI BERRY EXTRACTS FOR TREATMENT OF SKIN DISEASESNovember 2021October 2025Allow4811NoNo
17506680HERBAL CONFECTIONERY CANDY FOR EYESIGHT IMPROVINGOctober 2021May 2023Abandon1921NoNo
17502531HEMP AND PEA FORMULATION AND ITS USEOctober 2021June 2025Allow4411YesNo
17501309COMPOUND FOR TREATING OXIDATIVE STRESS IN MAMMALSOctober 2021June 2022Allow811NoNo
17432327PRODUCTION PROMOTER OF TYPE I COLLAGEN OR ELASTINAugust 2021July 2025Abandon4720YesNo
17400409COMPOSITIONS AND METHOD FOR TREATING AND PREVENTING COMPLICATIONS OF OBESITYAugust 2021February 2024Allow3051YesNo
17428968CANNABINOID CONTAINING COMPOSITION, METHODS OF PREPARATION AND USE THEREOFAugust 2021August 2025Abandon4811NoNo
17380787METHODS AND COMPOUND FOR THE TREATMENT OF MALARIAJuly 2021May 2024Abandon3410NoNo
17379804DEVICES AND METHODS FOR TREATING EAR PAINJuly 2021February 2024Allow3111NoNo
17375715ANTIBACTERIAL AND ANTIVIRUS COMPOSITION COMPRISING Extract of CANNABIS SATIVA L.July 2021June 2024Abandon3521NoNo
17370994USE OF GRAPE AND/OR SOY SUPPLEMENTS AGAINST COVID-19 AND 92 OTHER VIRUSES AND BACTERIA INCLUDING OTHER UNKNOWN VIRUSES AND BACTERIAJuly 2021February 2024Abandon3110NoNo
17368410SEBUM CONTROL AND ANTI-ACNE COMPOSITIONJuly 2021May 2025Abandon4620YesNo
17417061CANNABINOID FORMULATIONS AND METHODS OF MAKING SAMEJune 2021August 2025Abandon5011NoNo
17351621Cannabinoid-Containing CompositionJune 2021September 2024Abandon3901NoNo
17334016Hair Growth CompositionsMay 2021June 2024Abandon3721NoNo
17332778COMPOSITIONS AND METHODS FOR TREATING COVID-19 INFECTIONS WITH AN EXTRACT OF DICHROSTACHYS GLOMERATAMay 2021June 2024Allow3720YesNo
17297299METHOD FOR PRODUCING RED PERILLA LEAF EXTRACTMay 2021October 2024Abandon4110NoNo
17240947DEVICES AND METHODS FOR PROMOTING DRAINAGE OF FLUID FROM A EUSTACHIAN TUBEApril 2021May 2025Allow4930NoYes
17239083CONTROLLED DECARBOXYLATION OF ACTIVE COMPOUNDSApril 2021August 2024Abandon4001NoNo
17207339COMPOUND FOR TREATING OXIDATIVE STRESS IN CANINESMarch 2021December 2022Allow2131NoNo
17204245COMPOSITION INCLUDING LACTIC ACID BACTERIAL STRAIN AND HERBAL EXTRACT FOR PROMOTING DEFECATIONMarch 2021October 2023Allow3121NoNo
17276146USE OF NUCIFERIN AND LOTUS LEAF EXTRACT IN THE PREPARATION OF A MEDICAMENT FOR TREATING ATROPHIC GASTRITIS AND/OR BLOCKING TRANSFORMATION OF GASTRITIS INTO CANCERMarch 2021December 2024Abandon4641NoYes
17198102EDIBLE, SINGLE-EXTRACTION CURCUMA EXTRACTSMarch 2021April 2024Allow3711NoNo
17273917INFLAMMATORY CYTOKINE PRODUCTION INHIBITORMarch 2021September 2025Abandon5520NoNo
17260891INFLAMMATORY CYTOKINE PRODUCTION INHIBITORMarch 2021July 2024Abandon4120NoNo
17179447COMPOSITIONS AND METHODS FOR THE TREATMENT OF CORONAVIRUS INFECTIONFebruary 2021September 2022Allow1931YesNo
17169666DISCOVERY OF POTENT [ALPHA]-GLUCOSIDASE INHIBITORS FROM HETEROPHRAGMA ADENOPHYLLUMFebruary 2021August 2022Allow1841NoNo
17266760FORMULATIONS CONTAINING LIPOPHILIC EXTRACTS OF SPICY EDIBLE PLANTS USEFUL IN CONTROLLING PAIN AND INFLAMMATIONFebruary 2021December 2023Abandon3511NoNo
17168483HERBAL SUPPLEMENTS AND METHODS OF USE THEREOFFebruary 2021December 2023Allow3411NoNo
17143757STABLE VITAMIN C COMPOSITIONSJanuary 2021May 2023Allow2811NoNo
17257229LIPID EMULSION FOR PARENTERAL ADMINISTRATIONDecember 2020January 2026Allow6051YesNo
17251027COMPOSITION FOR IMPROVING INTESTINAL FLORADecember 2020March 2024Abandon4021YesNo
17114217COMPOUND FOR TREATING OXIDATIVE STRESS IN MAMMALSDecember 2020April 2022Abandon1721NoNo
17105628ANTIDEPRESSANT COMPOUND PREPARATION AND PREPARATION METHOD THEREOFNovember 2020January 2023Allow2501NoNo
17056887ANGIOTENSIN I-CONVERTING ENZYME ACTIVITY INHIBITORNovember 2020February 2023Abandon2710NoNo
17054764COMPOSITION COMPRISING CLEMATIS MANDSHURICA EXTRACT AS ACTIVE INGREDIENT FOR COGNITIVE FUNCTION IMPROVEMENTNovember 2020March 2024Abandon4131NoNo
17067489COMPOSITIONS WITH PURIFIED BOMBYX MORI COCOON SILK PEPTIDE FIBER AND REFINED BUGLOSSOIDES ARVENSIS SEED OIL HAVING SYNERGISTIC EFFECTS FOR IMPROVING MEMORY, FOCUS, AND COGNITIVE FUNCTION, AND RELATED METHODSOctober 2020March 2022Allow1811YesNo
17043737TRADITIONAL CHINESE MEDICINE EXTRACT COMPOSITION WITH FUNCTION OF REGULATING DEPRESSIVE EMOTION AND PREPARATION METHOD AND TRADITIONAL CHINESE MEDICINE PREPARATION THEREOFSeptember 2020December 2024Abandon5111NoNo
17042263RETINOL REPLACEMENT IN SKIN TREATMENTSeptember 2020June 2023Allow3221YesNo
17002265METHODS FOR EXTRACTION OF MELANIN FROM FUNGAL SPECIESAugust 2020February 2024Abandon4221NoNo
17002461HERBAL FORMULATIONS OF CARNIVOROUS PLANTS AND METHODS FOR TREATING INFLAMMATIONAugust 2020January 2025Allow5321NoNo
16967857COMPOSITION FOR THE PREVENTION AND TREATMENT OF DISEASES OF THE RESPIRATORY TRACTAugust 2020August 2024Abandon4921NoNo
16928200Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive DisordersJuly 2020October 2023Allow3911NoNo
16895990COMPOSITIONS CONTAINING NATURAL EXTRACTS AND USE THEREOF FOR SKIN AND HAIRJune 2020November 2022Abandon3001NoNo
16882741EXTRACT EFFECTIVE IN TREATING DRUG ADDICTIONMay 2020January 2024Allow4441NoNo
16763854COMPOSITIONS INCLUDING PINE BARK EXTRACT, BERRYFRUIT EXTRACT AND A SOURCE OF L-THEANINE AND USES THEREOFMay 2020October 2025Allow6031YesNo
16838661PRESERVATIVE COMPOSITIONApril 2020July 2022Abandon2810NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHEN, CATHERYNE.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
5
Examiner Affirmed
4
(80.0%)
Examiner Reversed
1
(20.0%)
Reversal Percentile
31.1%
Lower than average

What This Means

With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
129
Allowed After Appeal Filing
47
(36.4%)
Not Allowed After Appeal Filing
82
(63.6%)
Filing Benefit Percentile
60.1%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 36.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner CHEN, CATHERYNE - Prosecution Strategy Guide

Executive Summary

Examiner CHEN, CATHERYNE works in Art Unit 1655 and has examined 891 patent applications in our dataset. With an allowance rate of 32.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.

Allowance Patterns

Examiner CHEN, CATHERYNE's allowance rate of 32.8% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CHEN, CATHERYNE receive 2.38 office actions before reaching final disposition. This places the examiner in the 68% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CHEN, CATHERYNE is 43 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +20.9% benefit to allowance rate for applications examined by CHEN, CATHERYNE. This interview benefit is in the 65% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 14.0% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 23.2% of cases where such amendments are filed. This entry rate is in the 31% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 147.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 89% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 93.5% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 62.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 75.3% are granted (fully or in part). This grant rate is in the 81% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.8% of allowed cases (in the 82% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.